Company
Overview
Management Team
News Releases
Careers
Contact Us

FOR IMMEDIATE RELEASE

Research Identifying Prognostic Biomarkers for Biliary Tract Cancer Using Aushon’s Cira™ Platform Published in the Lancet Oncology

Billerica, Mass. — July 28, 2015 Aushon BioSystems, a leading provider of multiplex immunoassay products and services, today announced publication in The Lancet Oncology of results from a clinical trial featuring biomarker data using Aushon’s multiplex Cira™ platform.

Led by Juan W. Valle, M.D., of The Christie NHS Foundation Trust and University of Manchester, and supported by researchers from a number of leading research hospitals in the UK and funding by Cancer Research UK and AstraZeneca Pharmaceuticals, the study was based on a randomized phase II clinical trial (UK ABC-03) of patients with advanced biliary tract cancer who were either treated with cediranib (AZD2171), a pan-VEGF receptor tyrosine kinase inhibitor with activity against PDGF receptors and c-KIT, or placebo in combination with cisplatin/gemcitabine chemotherapy. Previous to this study, no randomized trial had shown superiority of any systemic therapy over the current reference treatment, chemotherapy with cisplatin and gemcitabine.

VEGF and its receptors are known to be overexpressed in patients with biliary tract cancer, correlating with an adverse prognosis. As part of the study, testing was conducted for 15 specific circulating angiogenesis and inflammation biomarkers using Aushon’s multiplex Cira™ platform to assess the effect of adding cediranib to the reference treatment in a double-blind, placebo-controlled manner. Although baseline concentrations were not correlated with treatment effect, VEGFR2 was identified as a novel adverse prognostic marker for overall survival in this disease.

Researchers concluded that while the addition of cediranib to cisplatin and gemcitabine chemotherapy did not improve progression-free survival, VEGF inhibition might still be worth pursuing, possibly with an agent which would allow for more sustained dosing than cediranib. Furthermore, several other biomarkers in addition to VEGFR2 were deemed to merit further exploration in future clinical trials.

http://dx.doi.org/10.1016/S1470-2045(15)00139-4

About Aushon BioSystems

Aushon BioSystems, Inc. provides a comprehensive suite of multiplex immunoassay products and services for protein biomarker discovery, development, and analysis to leading pharmaceutical, biotechnology, academic, and diagnostic clients worldwide. Our unique combination of proprietary microarray printing, extensive biomarker content, and innovative Cira immunoassay platform delivers exceptional performance, quality, and reliability to accelerate preclinical and clinical biomarker research. Our customers, who include leading pharmaceutical companies and translational research centers, trust Aushon to supply the most reliable biomarker data available, accelerating the evaluation of potential drug candidates and advancing the use of biomarker profiles in therapeutics.

http://www.aushon.com

Media Contact
Susan Vogt
Chief Executive Officer
Aushon BioSystems
info@aushon.com
978-436-6400

<< back

Aushon BioSystems
43 Manning Rd
Billerica, MA 01821
1-877-287-4661
978-436-6400
info@aushon.com